FDA’s compounding committee reviewed BPC-157. Nothing was added to any list.
Arkham Labs editorial/Published 12 September 2026/Corrections policy
The Pharmacy Compounding Advisory Committee considered BPC-157 for possible inclusion on the 503A Bulks List, for the proposed use of ulcerative colitis. Advisory recommendations are non-binding, nothing was added as a result, and inclusion would require formal rulemaking. This note exists because a committee reviewing a substance is routinely reported as a regulator endorsing one.
No grade change.
Guides affected by this note: BPC-157.
Field notes record what changed in the library. Where the effect on a grade is none, that is stated rather than omitted — a note saying nothing changed is the same evidence as a note saying something did.
For laboratory research use only. Not for human consumption. Nothing here is medical advice.